BR112023005697A2 - Tratamento de condições dermatológicas - Google Patents

Tratamento de condições dermatológicas

Info

Publication number
BR112023005697A2
BR112023005697A2 BR112023005697A BR112023005697A BR112023005697A2 BR 112023005697 A2 BR112023005697 A2 BR 112023005697A2 BR 112023005697 A BR112023005697 A BR 112023005697A BR 112023005697 A BR112023005697 A BR 112023005697A BR 112023005697 A2 BR112023005697 A2 BR 112023005697A2
Authority
BR
Brazil
Prior art keywords
treatment
dermatological conditions
cutaneous
patient
pharmaceutical composition
Prior art date
Application number
BR112023005697A
Other languages
English (en)
Inventor
Menne Torkil
Selmer Johan
Lange Jesper
Bondebjerg Jon
Georgiou Michelle
Original Assignee
Mc2 Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mc2 Therapeutics Ltd filed Critical Mc2 Therapeutics Ltd
Publication of BR112023005697A2 publication Critical patent/BR112023005697A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO DE CONDIÇÕES DERMATOLÓGICAS. A presente invenção refere-se a uma composição farmacêutica que é fornecida, que compreende um composto nucleofílico capaz de inibir a carbamilação, para uso no tratamento de uma condição envolvendo dano do tecido cutâneo ou conjuntivo. Um método para tratar uma condição envolvendo o dano do tecido cutâneo ou conjuntivo em um paciente, é também fornecido, o dito método compreendendo administrar a dita composição farmacêutica para o dito paciente.
BR112023005697A 2020-10-09 2021-10-08 Tratamento de condições dermatológicas BR112023005697A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20201040 2020-10-09
PCT/EP2021/077931 WO2022074228A1 (en) 2020-10-09 2021-10-08 Treatment of dermatological conditions

Publications (1)

Publication Number Publication Date
BR112023005697A2 true BR112023005697A2 (pt) 2023-04-25

Family

ID=72826736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005697A BR112023005697A2 (pt) 2020-10-09 2021-10-08 Tratamento de condições dermatológicas

Country Status (11)

Country Link
US (1) US20230414699A1 (pt)
EP (1) EP4225293A1 (pt)
JP (1) JP2023545753A (pt)
KR (1) KR20230084242A (pt)
CN (1) CN116322671A (pt)
AU (1) AU2021356164A1 (pt)
BR (1) BR112023005697A2 (pt)
CA (1) CA3196808A1 (pt)
IL (1) IL301915A (pt)
MX (1) MX2023003569A (pt)
WO (1) WO2022074228A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1773600A (en) * 1998-12-21 2000-07-12 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
CA2604758C (en) * 2005-04-13 2014-11-25 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
ES2843052T3 (es) 2017-12-14 2021-07-15 Bitop Ag Ectoína y derivados de ectoína para su uso en afecciones vulvovaginales

Also Published As

Publication number Publication date
EP4225293A1 (en) 2023-08-16
IL301915A (en) 2023-06-01
JP2023545753A (ja) 2023-10-31
CN116322671A (zh) 2023-06-23
US20230414699A1 (en) 2023-12-28
AU2021356164A1 (en) 2023-06-15
CA3196808A1 (en) 2022-04-14
KR20230084242A (ko) 2023-06-12
MX2023003569A (es) 2023-04-04
WO2022074228A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112022019557A2 (pt) Inibidores de replicação de norovírus e coronavírus
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112022022761A2 (pt) Inibidor de sos1 contendo fósforo
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
BR112012006010A2 (pt) composto de glicina
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
BR112022016360A2 (pt) Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112015005467A2 (pt) métodos de tratar condições relacionadas ao cabelo
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112023005697A2 (pt) Tratamento de condições dermatológicas
BR112018016820A2 (pt) uso de uma dieta simulando jejum para aumentar a eficácia dos antiestrogênios na terapia contra o câncer
BR112015027984A2 (pt) Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
BR112014005730A2 (pt) método de tratar carcinoma mucoepidermóide
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp